Actinogen Medical Limited (ASX: ACW) is progressing its lead drug candidate, Xanamem (emestedastat), through the XanaMIA Phase 2b/3 Alzheimer’s disease clinical trial being conducted across Australia and the United States. The Company is developing Xanamem as a once-daily oral therapy targeting cortisol regulation in the brain, to slow disease progression in patients with mild to moderate Alzheimer’s disease.

The Australian healthcare sector continues to attract investor attention as companies progress from early development into clinical validation, regulatory approval, and commercial execution. This ASX Companies Snapshot & Market Position provides a concise, side-by-side overview of selected ASX-listed healthcare companies, outlining what each business does, where it sits within the market, and how it is currently positioned from a market capitalisation and execution perspectiv

Actinogen Medical Limited (ASX: ACW) has announced a significant milestone in the development of Xanamem®, its lead therapy for Alzheimer’s disease (AD). Following a successful Type C meeting with the US Food and Drug Administration (FDA), the Company now has clear guidance on the remaining clinical, manufacturing, and regulatory requirements for a New Drug Application (NDA) submission in the US.

Actinogen Medical Limited (ASX: ACW) has added another important milestone in its clinical development journey, showcasing new data that reinforces the mechanism and therapeutic promise of Xanamem® (emestedastat). The company’s Chief Medical Officer, Dr Dana Hilt, and Senior Clinical Scientist, Dr Jack Taylor, are presenting a scientific poster at the prestigious Alzheimer’s Association International Conference (AAIC 2025) in Toronto, the world’s largest platform for dementia